Axsome stock jumped Wednesday after the biotech firm said its Alzheimer's disease agitation drug will get a priority review.

Axsome Therapeutics recently reported that the FDA accepted its supplemental application and granted priority review for AXS-05 to treat agitation in Alzheimer’s disease, while also confirming that ...

In a report released today, Ashwani Verma from UBS maintained a Buy rating on Axsome Therapeutics, with a price target of $248.00. Claim 70% Off TipRanks Premium. Unlock hedge fun ...

H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $200 from $185 and keeps a Buy rating on the shares after the ...

Axsome Therapeutics (AXSM) has quickly moved onto investors' radar after the FDA accepted a priority review for AXS-05 in Alzheimer’s agitation and signaled support for an NDA filing for narcolepsy ...

As of Wednesday, December 31, Axsome Therapeutics, Inc.’s AXSM share price has surged by 17.93%, which has investors ...

A CNS-focused biopharmaceutical company headquartered in New York City. The company commercializes products in the United ...

The US Food and Drug Administration (FDA) has accepted for filing Axsome Therapeutics’ supplemental New Drug Application (NDA ...

FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026NEW YORK, (GLOBE NEWSWIRE) -- ...

Axsome Therapeutics (NASDAQ: AXSM) has had a transformative past 10 months. The biotech company started the year with no drugs on the market, and now its portfolio includes two therapies. That's ...

Shares of Axsome Therapeutics (NASDAQ: AXSM) were sinking 6.8% lower as of 11:19 a.m. ET on Tuesday. The decline came after Culper Research announced a short position in the biotech stock before the ...

Axsome Therapeutics has been a short-term and long-term winner when it comes to share-price performance. The company last year launched its first two products, and there may be more to come. Axsome's ...